Journal issues > Issue 6, October 2022 > A novel treatment option in chronic myeloid leukaemia: Asciminib

A novel treatment option in chronic myeloid leukaemia: Asciminib

SUMMARY

Despite the success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia, there are some patients who fail these drugs because of intolerance or lack of efficacy. Asciminib is a first-in-class STAMP-inhibitor (Specifically Targeting the ABL Myristoyl Pocket) and has a different mode of action as the classical tyrosine kinase inhibitors. Clinical trials, most recently the phase III ASCEMBL trial, show clinical activity in heavily pre-treated patients with an acceptable safety profile. Asciminib therefore forms a promising treatment option for those patients failing the currently available drugs.

(BELG J HEMATOL 2022;13(6):243–8)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top